Re-treatment versus extended treatment strategy of systemic bevacizumab in hereditary hemorrhagic telangiectasia: which is better?
Hereditary hemorrhagic telangiectasia (HHT) is an autosomal dominant vascular disorder characterized by a multisystem vascular dyscrasia leading to severe and recurrent epistaxis and gastrointestinal (GI) hemorrhages from mucocutaneous telangiectases and development of arteriovenous malformations (AVM), most commonly in the lung, liver, brain, and spine [1, 2, 3, 4]. In patients with HHT, vascular endothelial growth factor (VEGF) levels in circulation are elevated  forming the basis for utilization of bevacizumab, a VEGF inhibitor, in this disease state. Intravenous (IV) administration of bevacizumab has been shown to be effective in improving epistaxis and telangiectasias, reducing the need for red blood cell (RBC) transfusions, and improvement in the high output cardiac failure [5, 6, 7, 8]. However, it is unclear as to the optimal dosing strategy of IV bevacizumab in patients with HHT. Hence, we aimed to determine whether re-treatment strategy or extended dosing...
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
- 4.Sadick H, Riedel F, Naim R, Goessler U, Hormann K, Hafner M et al (2005) Patients with hereditary hemorrhagic telangiectasia have increased plasma levels of vascular endothelial growth factor and transforming growth factor-beta1 as well as high ALK1 tissue expression. Haematologica 90(6):818–828PubMedGoogle Scholar